[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053991":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":71,"centralContacts":75,"locations":83,"responsibleParty":100,"collaborators":102,"id":106,"slug":107,"hasResults":108,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":32,"eligibilityCriteria":111,"healthyVolunteers":112,"sex":113,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":32,"studyType":119,"phases":120,"briefSummary":122,"conditions":123,"keywords":32,"overallStatus":85,"whyStopped":32,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},{"fullName":5,"class":6},"Washington University School of Medicine","OTHER",[8,22],{"label":9,"type":6,"description":10,"interventionNames":11},"Family History of Migraine","This group has a first degree relative diagnosed with migraine.",[12,13,14,15,16,17,18,19,20,21],"Device: MRI","Device: Thermal Stimuli","Device: Pressure stimuli","Behavioral: Pain ratings","Behavioral: Pressure pain thresholds (PPT)","Behavioral: Conditioned pain modulation (CPM) efficiency","Diagnostic Test: Hormonal assessment","Behavioral: Migraine-related measures","Behavioral: Neural assessments","Diagnostic Test: Pubertal status",{"label":23,"type":6,"description":24,"interventionNames":25},"No Family History of Migraine","This group does not have a first or second degree relative diagnosed with migraine.",[12,13,14,15,16,17,18,19,20,21],[27,33,37,41,46,50,54,59,63,67],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DEVICE","MRI","Grey Matter Volume (T1) Resting state BOLD",[9,23],null,{"type":28,"name":34,"description":35,"armGroupLabels":36,"otherNames":32},"Thermal Stimuli","The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to safely deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.",[9,23],{"type":28,"name":38,"description":39,"armGroupLabels":40,"otherNames":32},"Pressure stimuli","Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.",[9,23],{"type":42,"name":43,"description":44,"armGroupLabels":45,"otherNames":32},"BEHAVIORAL","Pain ratings","Pain intensity and pain unpleasantness ratings will be assessed by numerical rating scale (ranging from 0- no pain\u002Funpleasantness to- 10 or 100 the most intense\u002Funpleasantness pain imaginable) and by mechanical and computerized visual analog scales (VAS which ranges between ''no pain sensation'' and ''most intense pain imaginable'').",[9,23],{"type":42,"name":47,"description":48,"armGroupLabels":49,"otherNames":32},"Pressure pain thresholds (PPT)","Pressure will be increased continually and participants will be instructed to press a button the first moment they feel pain from the pressure stimulus.",[9,23],{"type":42,"name":51,"description":52,"armGroupLabels":53,"otherNames":32},"Conditioned pain modulation (CPM) efficiency","The CPM paradigm assesses endogenous inhibitory pain modulation efficiency related to spatial filtering of nociceptive information.",[9,23],{"type":55,"name":56,"description":57,"armGroupLabels":58,"otherNames":32},"DIAGNOSTIC_TEST","Hormonal assessment","Blood samples will be collected for analyses of sex hormone levels",[9,23],{"type":42,"name":60,"description":61,"armGroupLabels":62,"otherNames":32},"Migraine-related measures","Adolescents with migraine will complete questions regarding their headache frequency and migraine symptoms.",[9,23],{"type":42,"name":64,"description":65,"armGroupLabels":66,"otherNames":32},"Neural assessments","MRI and fMRI scans",[9,23],{"type":55,"name":68,"description":69,"armGroupLabels":70,"otherNames":32},"Pubertal status","Pubertal status will be assessed using the self-reported Physical Developmental Scale-",[9,23],[72],{"name":73,"affiliation":5,"role":74},"Hadas Nahman-Averbuch, PhD","PRINCIPAL_INVESTIGATOR",[76,81],{"name":77,"role":78,"phone":79,"phoneExt":32,"email":80},"Alana McMichael, MA","CONTACT","314-273-6194","painlab@wustl.edu",{"name":82,"role":78,"phone":79,"phoneExt":32,"email":32},"Hadas Nahman-Averbuch",[84],{"facility":5,"status":85,"city":86,"state":87,"zip":88,"country":89,"countryCode":90,"cosmosGeoPoint":91,"geoPoint":96,"contacts":97},"RECRUITING","St Louis","Missouri","63110","United States","US",{"type":92,"coordinates":93},"Point",[94,95],-90.19789,38.62727,{"lat":95,"lon":94},[98,99],{"name":73,"role":78,"phone":79,"phoneExt":32,"email":80},{"name":77,"role":78,"phone":79,"phoneExt":32,"email":80},{"type":74,"investigatorFullName":82,"investigatorTitle":101,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"Asst Prof of Anesthesiology",[103],{"name":104,"class":105},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH","100053991","migraine-in-adolescents-100053991",false,"NCT05654012","Migraine in Adolescents","Inclusion criteria for healthy participants:\n\n1. Age 10-13\n2. Males or females (biological sex)\n3. Not diagnosed with migraine or having migraine symptoms\n4. With a first degree relative diagnosed with migraine (for the Fam-His group) or without a first or a second degree relative diagnosed with migraine (for the No-Fam-His group)\n\nInclusion criteria for participants with migraine:\n\n1. Age 10-13\n2. Males or females (biological sex)\n3. Diagnosed with migraine or having migraine symptoms\n4. Migraine duration \\> 6 months\n5. Without preventative treatment or with stable preventative treatment for migraine (no change in intervention in the last 6 months)\n\nExclusion Criteria for the healthy group:\n\n* Participants will not be enrolled if any of the following criteria exist and based on the investigator discretion:\n\n  1. Diagnosis of any chronic pain syndrome\n  2. Diagnosis of a neurological, developmental, pubertal, or psychiatric disorder\n  3. Taking pain or psychiatric medications regularly\n  4. Having an MRI contraindication such as metal in the body or claustrophobia\n  5. Not able to understand and communicate in English\n\n     Exclusion Criteria for the migraine group\n* Participants will not be enrolled if any of the following criteria exist and based on the investigator discretion:\n\n  1. Diagnosis of any chronic pain syndrome other than migraine\n  2. Diagnosis of a neurological, developmental, pubertal, or psychiatric disorder\n  3. Having an MRI contraindication such as metal in the body or claustrophobia\n  4. Not able to understand and communicate in English",true,"ALL","10 Years","13 Years",{"count":117,"type":118},250,"ESTIMATED","INTERVENTIONAL",[121],"NA","Aim 1. To identify psychophysical and neural factors predicting migraine onset in adolescents\n\nAim 2a. To determine hormonal, psychophysical, and neural changes associated with migraine onset.\n\nAim 2b. To identify the temporal relationships between hormonal, psychophysical, and neural changes preceding vs. following migraine onset.\n\nAim 3. To identify psychophysical and neural factors predicting migraine prognosis in adolescents with migraine.",[124],"Migraine","2026-07-10",{"date":127,"type":128},"2026-07-13","ACTUAL",{"date":130,"type":128},"2023-06-01",{"date":132,"type":118},"2030-03-15",{"name":5,"class":6},1]